Scot RobertsCSO at Altimmune (NASDAQ: ALT)
Dr. Roberts has served as the chief scientific officer (CSO) for Altimmune since December 2012. He has two decades of experience managing scientific operations – leading small molecule and biologics research and drug development efforts with a focus on viral vectors and antiviral therapies. Prior to joining Altimmune, Dr. Roberts served as CSO for ImQuest BioSciences, Inc., where he led scientific operations and business development initiatives in cancer and antivirals. Dr. Roberts held multiple leadership positions at Wellstat Biologics Corporation from August 1996 to October 2010, including director of research and development where he was responsible for a portfolio of biologic candidates in oncology including a clinical-stage asset. He also led bioassay and upstream process development efforts, and the animal pharmacology program at Wellstat. Dr. Roberts completed a post-doctoral fellowship at the National Cancer Institute, Laboratory of Molecular Virology and received his Ph.D. from the Johns Hopkins School of Medicine, Department of Pharmacology and Molecular Sciences. He has numerous patents, peer-reviewed journal publications and has been invited to speak and chair numerous international conferences.